NovoCure Ltd
NVCR· Nasdaq
NVCRNovoCure Ltd
Filed Feb 26, 2026 · 10-K · 57 days after period end · 0001645113-26-000017
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022 |
|---|---|---|---|---|
| Revenue | $174.35M | $161.27M | $133.78M | $128.43M |
| Net Income | -$24.50M | -$65.92M | -$47.08M | -$37.30M |
| EPS Diluted | — | — |
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
| — |
| -$0.36 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2025 · filed Feb 26, 2026 · 57 d after period end
